Human Anti-NGF Neutralizing Antibodies As Selective NGF Pathway Inhibitors
AssigneesAmgen Inc., E.R. Squibb & Sons, Inc.
InventorsKenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
Life of this patent
Estimating the term…
Abstract
This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
Claims19
An isolated antibody or an antigen-binding fragment thereof that binds specifically to nerve growth factor (NGF), wherein the antibody or fragment comprises a heavy chain variable region and a light chain variable region,
- wherein the heavy chain variable region comprises a CDR1 selected from SEQ ID NO:
- 22, SEQ ID NO:
- 92, SEQ ID NO:
- 98, SEQ ID NO:
- 104, SEQ ID NO:
- 110, or SEQ ID NO:
- 116;
- a CDR2 selected from SEQ ID NO:
- 18, SEQ ID NO:
- 93, SEQ ID NO:
- 99, SEQ ID NO:
- 105, SEQ ID NO:
- 111, or SEQ ID NO:
- 117;
- and a CDR3 selected from SEQ ID NO:
- 14, SEQ ID NO:
- 94, SEQ ID NO:
- 100, SEQ ID NO:
- 106, SEQ ID NO:
- 112, or SEQ ID NO:
- 118;
- and
- wherein the light chain variable region comprises a CDR1 selected from SEQ ID NO:
- 24, SEQ ID NO:
- 95, SEQ ID NO:
- 107, SEQ ID NO:
- 113, SEQ ID NO:
- 119, SEQ ID NO:
- 122, SEQ ID NO:
- 125, SEQ ID NO:
- 128, or SEQ ID NO:
- 132;
- a CDR2 selected from SEQ ID NO:
- 20, SEQ ID NO:
- 96, SEQ ID NO:
- 108, SEQ ID NO:
- 114, SEQ ID NO:
- 120, SEQ ID NO:
- 123, SEQ ID NO:
- 126, SEQ ID NO:
- 129, or SEQ ID NO:
- 133;
- and a CDR3 selected from SEQ ID NO:
- 16, SEQ ID NO:
- 97, SEQ ID NO:
- 109, SEQ ID NO:
- 115, SEQ ID NO:
- 121, SEQ ID NO:
- 124, SEQ ID NO:
- 127, SEQ ID NO:
- 130, or SEQ ID NO:
- 134.
A recombinant antibody that specifically binds to human NGF comprising a heavy chain variable region and a light chain variable region, wherein the antibody is isolated from a host cell that expresses a heavy chain variable region nucleic acid comprising the sequence of SEQ ID NO:
- 9 and a light chain variable region nucleic acid comprising the sequence of SEQ ID NO:
- 11.
Dependencies are inferred from the claim text.